Sierra Oncology, Inc. Common Stock
SRRA
SRRA was delisted on the 30th of June, 2022.
22 hedge funds and large institutions have $67M invested in Sierra Oncology, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 17 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
11% less capital invested
Capital invested by funds: $75.2M → $67M (-$8.16M)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
24% less funds holding
Funds holding: 29 → 22 (-7)
35% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$25.1M |
| 2 |
O
OrbiMed
New York
|
+$19.4M |
| 3 |
A
Abingworth
London,
United Kingdom
|
+$11.4M |
| 4 |
CC
Caxton Corporation
Princeton,
New Jersey
|
+$8.44M |
| 5 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$5.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$470K |
| 2 |
HP
Hikari Power
Tokyo,
Japan
|
-$171K |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
-$132K |
| 4 |
GT
Greenleaf Trust
Kalamazoo,
Michigan
|
-$74K |
| 5 |
WG
Winton Group
London,
United Kingdom
|
-$62K |
SRRA Hedge Fund Activity: Q1 2020 in Review
22 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Sierra Oncology, Inc. Common Stock (SRRA) for Q1 2020, worth a combined $67M — down 11% from $75.2M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of SRRA and 11 opened new positions — a net loss of 6 holders — while 5 trimmed existing stakes and 4 added.
The largest buyer was Vivo Capital, opening a new position worth an estimated $25.1M. The largest seller was Acadian Asset Management, exiting entirely with an estimated $470K sold.
- 22 institutional investors held Sierra Oncology, Inc. Common Stock (SRRA) as of Q1 2020, down from 29 in Q4 2019.
- Funds reported $67M of Sierra Oncology, Inc. Common Stock stock for Q1 2020, down 11% quarter-over-quarter.
- 11 funds opened new Sierra Oncology, Inc. Common Stock positions in Q1 2020 and 17 closed out, a net change of -6 holders.
- The largest Sierra Oncology, Inc. Common Stock buyer in Q1 2020 was Vivo Capital, an estimated $25.1M added.
- The largest Sierra Oncology, Inc. Common Stock seller in Q1 2020 was Acadian Asset Management, an estimated $470K sold.
Based on aggregated 13F filings for Q1 2020.